New Data: STIOLTO(R) RESPIMAT(R) (tiotropium bromide+olodaterol) Inhalation Spray Significantly Improved Exercise Capacity in People with COPD

RIDGEFIELD, Conn., Sept. 5, 2016 -- (Healthcare Sales & Marketing Network) -- Boehringer Ingelheim today announced the first results from the Phase IIIb/IV PHYSACTO trial that showed STIOLTO RESPIMAT, combined with exercise training, helps people with COP... Biopharmaceuticals, Devices, Drug Delivery Boehringer Ingelheim, STIOLTO RESPIMAT, tiotropium, olodaterol, COPD
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news